Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12514075 | 1.00 | EPHX2 (0.61) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL20687037 | 1.00 | EPHX2 (0.61) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL14703719 | 0.94 | EPHX2 (0.56) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL14037774 | 0.94 | EPHX2 (0.56) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL20542716 | 0.92 | LPAR3 (0.62) | EPHX2LPAR3LPAR1 | |
| SCHEMBL20542720 | 0.92 | LPAR3 (0.62) | EPHX2LPAR3LPAR1 | |
| SCHEMBL16214777 | 0.91 | EPHX2 (0.55) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL15462785 | 0.91 | EPHX2 (0.55) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12148864 | 0.89 | EPHX2 (0.60) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL13367166 | 0.88 | EPHX2 (0.65) | EPHX2SLC6A5LPAR3LPAR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | EPHX2 2326/4885SLC6A5 1755/4885LPAR3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.